Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Mithra Pharmaceuticals SA
  6. Summary
    MITRA   BE0974283153

MITHRA PHARMACEUTICALS SA

(MITRA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
24.3(c) 23.95(c) 23.9(c) 23.95(c) 23.75(c) Last
53 048 47 923 44 982 28 218 154 200 Volume
+2.97% -1.44% -0.21% +0.21% -0.84% Change
More quotes
Financials
Sales 2021 71,8 M 85,3 M 85,3 M
Net income 2021 -27,9 M -33,1 M -33,1 M
Net Debt 2021 97,5 M 116 M 116 M
P/E ratio 2021 -50,4x
Yield 2021 -
Sales 2022 266 M 316 M 316 M
Net income 2022 145 M 172 M 172 M
Net cash position 2022 5,98 M 7,10 M 7,10 M
P/E ratio 2022 4,87x
Yield 2022 -
Capitalization 1 039 M 1 231 M 1 233 M
EV / Sales 2021 15,8x
EV / Sales 2022 3,88x
Nbr of Employees 229
Free-Float 59,5%
More Financials
Company
Mithra Pharmaceuticals SA is a Belgian-based company active in the pharmaceutical industry. The Company is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The Company provides three development... 
Sector
Pharmaceuticals
Calendar
06/22Presentation
More about the company
Ratings of Mithra Pharmaceuticals SA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about MITHRA PHARMACEUTICALS SA
05/28Mayne - Nextstellis Receives FDA Marketing Exclusivity And Phase III Data Pub..
AQ
05/27MAYNE PHARMA  : Nextstellis receives fda marketing exclusivity and phase iii dat..
AQ
05/27MITHRA PHARMACEUTICALS S A  : Nextstellis® Receives FDA Marketing Exclusivity an..
PU
05/21Today on Wall Street: Poor manufacturing data boosts indexes
05/21MITHRA PHARMACEUTICALS S A  : Announces European Approval of Estelle
AQ
05/20MITHRA PHARMACEUTICALS S A  : Announces European Approval of Estelle®
PU
05/20MITHRA PHARMACEUTICALS S.A.  : Proxy Statments
CO
05/06MITHRA PHARMACEUTICALS S.A.  : Crossing thresholds
CO
04/30MITHRA PHARMACEUTICALS S.A.  : Monthly statement on outstanding equity shares an..
CO
04/28MITHRA PHARMACEUTICALS S A  : takes note of François Fornieri's indictment
PU
04/21MITHRA PHARMACEUTICALS S A  : Releases 2020 Annual Report and Invitation to its ..
AQ
04/20MITHRA PHARMACEUTICALS S A  : Releases 2020 Annual Report and Invitation to its ..
PU
04/20MITHRA PHARMACEUTICALS S.A.  : Ordinary general shareholder meeting
CO
04/20MITHRA PHARMACEUTICALS S.A.  : Annual Report
CO
04/16MITHRA PHARMACEUTICALS S A  : Publication of a Transparency Notification Receive..
PU
More news
News in other languages on MITHRA PHARMACEUTICALS SA
06/17Mithra rekruteert patiënten voor coronamedicijn
05/27FDA verleent exclusiviteit aan anticonceptiepil Mithra
05/25KBC Securities verhoogt koersdoel Mithra
05/21STOCK MARKET PARIS : Toutes les nouvelles sont bonnes à prendre
05/21EN DIRECT DES MARCHES  : Total, Saint-Gobain, Vallourec, Derichebourg, Neoen, Ri..
More news
Chart MITHRA PHARMACEUTICALS SA
Duration : Period :
Mithra Pharmaceuticals SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MITHRA PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 35,48 €
Last Close Price 23,75 €
Spread / Highest target 70,2%
Spread / Average Target 49,4%
Spread / Lowest Target 38,9%
EPS Revisions
Managers and Directors
NameTitle
Leon Van Rompay Chief Executive Officer
Christophe Maréchal Chief Financial Officer
Patricia van Dijck Chairman
Patrick Kellens Chief Information Officer
Graham K. Dixon CSO, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
MITHRA PHARMACEUTICALS SA20.56%1 231
CSL LIMITED7.89%104 078
WUXI BIOLOGICS (CAYMAN) INC.28.50%71 827
BIOGEN INC.58.64%58 481
SAMSUNG BIOLOGICS CO.,LTD.1.21%48 692
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.21.49%44 555